KR930000489A - 설폰아미드 - Google Patents

설폰아미드 Download PDF

Info

Publication number
KR930000489A
KR930000489A KR1019920010205A KR920010205A KR930000489A KR 930000489 A KR930000489 A KR 930000489A KR 1019920010205 A KR1019920010205 A KR 1019920010205A KR 920010205 A KR920010205 A KR 920010205A KR 930000489 A KR930000489 A KR 930000489A
Authority
KR
South Korea
Prior art keywords
alkyl
alkoxy
hydroxy
hydrogen
methoxy
Prior art date
Application number
KR1019920010205A
Other languages
English (en)
Other versions
KR100235507B1 (ko
Inventor
부리 카스파르
클로젤 마르텡
피슈리 발터
히르쓰 죠르즈
뢰플러 베른트-미카엘
라무즈 헨리
Original Assignee
프리돌린 클라우스너, 롤란트 보러
에프.호프만-라 토슈 에이지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25687870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR930000489(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 프리돌린 클라우스너, 롤란트 보러, 에프.호프만-라 토슈 에이지 filed Critical 프리돌린 클라우스너, 롤란트 보러
Publication of KR930000489A publication Critical patent/KR930000489A/ko
Application granted granted Critical
Publication of KR100235507B1 publication Critical patent/KR100235507B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Lubricants (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Glass Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Bipolar Transistors (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

내용 없음

Description

설폰아미드
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 일반식(I)의 화합물 또는 이의 염.
    상기식에서, R1은 수소, 저급-알킬, 저급-알콕시, 저급-알킬티오, 할로겐 또는 트리플루오로메틸이고; R2는 수소, 할로겐, 저급-알콕시, 트리플루오로메틸 또는 -OCH2COORa이며; R3는 수소, 할로겐, 저급-알킬, 저급-알킬티오, 트리플루오로메틸, 사이클로알킬, 저급-알콕시 또는 트리플루오로 메톡시이거나; R2는 R3는 함께 부타디에닐, 메틸렌디옥시, 에틸렌디옥시 또는 이소프로필리덴디옥시이고; R4는 수소, 저급-알킬, 사이클로알킬, 트리플루오로메틸, 저급-알콕시, 저급 알킬티오, 저급-알킬티오-저급-알킬, 하이드록시-저급-알킬, 하이드록시-저급-알콕시, 저급-알콕시-저급-알킬, 하이드록시-저급-알콕시-저급-알킬, 하이드록시-저급-알콕시-저급-알콕시, 저급-알킬설피닐, 저급-알킬설포닐, 2-메톡시-3-하이드록시 프로폭시, 2-하이드록시-3-페닐프로필, 아미노-저급-알킬, 저급-알킬아미노-저급-알킬, 디-저급-알킬아미노-저급-알킬, 아미노, 저급-알킬아미노, 디-저급-알킬아미노, 아릴, 아미노, 아릴 아일티오, 아리리옥시, 아릴-저급-알킬 또는 헤테로사이클릭이며; R5는 수소, 저급-알킬, 저급-알카노일, 벤조일, 헤테로 사이클릴카보닐, 헤테로사이클릴메틸 또는 테트라 하이드로파란-2-일이고; R6내지 R9는 수소, 할로겐, 트리플루오로메틸, 저급-알킬, 저급-알콕시, 저급-알킬티오, 하이드록시, 하이드록시메틸, 시아노, 카복실, 포르밀, 메틸설피닐, 메틸설포닐, 메틸설포닐옥시 또는 저급-알킬옥시-카보닐옥시이거나, R7이 R6또는 R8과 함께는 부타디에닐, 메틸렌디옥시, 에틸렌디옥시 또는 이소프로필리덴디옥시이며; Z는 -O-, -S-, 에틸렌, 비닐렌, -CO-, -OCHR10- 또는 -SCHR10이고; R10은 수소 또는 저급-알킬이며; X 및 Y는 각각 독립적으로 O, S 또는 NH이거나, YR5는 또한 저급-알킬설피닐 또는 -OCH2CH(ORC)CH2ORd이며; Ra, Rb, Rc및 Rd는 각각 독립적으로 수소 또는 저급-알킬이거나, Rc와 Rd가 함께는 메틸렌, 에틸렌 또는 이소프로필리덴이고; n은 1, 2 또는 3이다.
  2. (S)-4-3급-부틸-N-[6-(2,3-디하이드록시-프로필옥시)-5-(2-메톡시-페녹시)-2-(4-미톡시페닐)-피리미딘-4-일]-벤젠설폰아미드.
  3. (RS)-4-3급-부-N-[5-(2-클로로-5-메톡시-페녹시)-2-에틸-6-(2-메틸설피닐-에톡시)-피리미딘-4-일]-벤젠설폰아미드.
  4. (RS)-N-[5-(2-클로로-5-메톡시-페녹시)-6-(2-메틸설피닐-에톡시)-피리미딘-4-일]-1,3-벤조디옥솔-5-설폰아미드.
  5. 4-3급-부틸-N-[6-(2-하이드록시-에톡시)-5-(2-메톡시-페녹시)-2-(피리미딘-2-일)-피리미딘-4-일]-벤젠설폰아미드.
  6. 제1항 내지 제5항중 어느 한 항의 화합물 및 통상적인 담체 및 보조제를 함유하는 약제학적 제제.
  7. 엔도텔린(endothelin) 활성과 관련된 질환, 특히 고혈압, 허혈, 혈관경련 및 협심증과 같은 순환계 질환을 치료하기 위한 약물의 제조에 있어서 활성 성분으로서의 제1항 내지 제5항중 어느 한 항에 따른 화합물의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920010205A 1991-06-13 1992-06-12 설폰아미드 및 이를 함유하는 약제학적 제제 KR100235507B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CH1760/91 1991-06-13
CH176091 1991-06-13
CH151692 1992-05-12
CH1516/92 1992-05-12

Publications (2)

Publication Number Publication Date
KR930000489A true KR930000489A (ko) 1993-01-15
KR100235507B1 KR100235507B1 (ko) 1999-12-15

Family

ID=25687870

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920010205A KR100235507B1 (ko) 1991-06-13 1992-06-12 설폰아미드 및 이를 함유하는 약제학적 제제

Country Status (34)

Country Link
US (1) US5292740A (ko)
EP (1) EP0526708B1 (ko)
JP (1) JPH0730042B2 (ko)
KR (1) KR100235507B1 (ko)
AT (1) ATE197044T1 (ko)
AU (1) AU653604B2 (ko)
BG (1) BG60831B2 (ko)
BR (1) BR9202219A (ko)
CA (1) CA2071193C (ko)
CY (2) CY2306B1 (ko)
CZ (1) CZ281434B6 (ko)
DE (2) DE10299047I2 (ko)
DK (1) DK0526708T3 (ko)
DZ (1) DZ1587A1 (ko)
EE (1) EE03028B1 (ko)
ES (1) ES2152222T4 (ko)
FI (1) FI112216B (ko)
GR (1) GR3035162T3 (ko)
HU (2) HU221203B1 (ko)
IE (1) IE921920A1 (ko)
IL (1) IL102138A (ko)
IS (1) IS2054B (ko)
LU (2) LU90975I2 (ko)
MX (1) MX9202747A (ko)
NL (1) NL300097I1 (ko)
NO (2) NO303826B1 (ko)
NZ (1) NZ243074A (ko)
PT (1) PT526708E (ko)
RO (1) RO111268B (ko)
RU (1) RU2086544C1 (ko)
SG (1) SG54209A1 (ko)
SK (1) SK279006B6 (ko)
TW (1) TW222625B (ko)
ZA (1) ZA924126B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100411358B1 (ko) * 1995-05-16 2004-07-05 다나베 세이야꾸 가부시키가이샤 술폰아미드유도체및그의제조방법

Families Citing this family (186)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5571821A (en) * 1993-05-20 1996-11-05 Texas Biotechnology Corporation Sulfonamides and derivatives thereof that modulate the activity of endothelin
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
DK0444166T3 (da) * 1989-08-30 1995-03-27 Irwin Fox Bortskaffelig oxidbærer til fjernelse af hydrogensulfid
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
TW224462B (ko) * 1992-02-24 1994-06-01 Squibb & Sons Inc
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
NZ247440A (en) * 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5420123A (en) * 1992-12-21 1995-05-30 Bristol-Myers Squibb Company Dibenzodiazepine endothelin antagonists
US5352800A (en) * 1993-03-11 1994-10-04 Merck & Co., Inc. Process for the production of a novel endothelin antagonist
US5420133A (en) * 1993-03-19 1995-05-30 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
US5334598A (en) * 1993-03-19 1994-08-02 Merck & Co., Inc. Six-membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives
US5374638A (en) * 1993-03-19 1994-12-20 Merck & Co., Inc. Six membered ring fused imidazoles substituted with phenoxyphenylacetic acid derivatives used to treat asthma
US5767310A (en) * 1993-03-19 1998-06-16 Merck & Co., Inc. Phenoxyphenylacetic acid derivatives
US5401745A (en) * 1993-03-19 1995-03-28 Merck & Co., Inc. Quinazolinones substituted with phenoxyphenylacetic acid derivatives
CA2121724A1 (en) * 1993-04-21 1994-10-22 Toshifumi Watanabe Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
DE59409631D1 (de) * 1993-07-15 2001-02-15 Hoffmann La Roche Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält
US5686478A (en) * 1993-07-20 1997-11-11 Merck & Co. Inc. Endothelin antagonists
US6140325A (en) * 1993-08-19 2000-10-31 Takeda Chemical Industries, Ltd. Thienopyrimidine derivatives, their production and use
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
AU691201B2 (en) * 1993-11-01 1998-05-14 Japat Ltd. Endothelin receptor antagonists
IL111959A (en) * 1993-12-17 2000-07-16 Tanabe Seiyaku Co N-(polysubstituted pyrimidin-4-yl) benzenesulfonamide derivatives their preparation and pharmaceutical compositions containing them
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) * 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5538991A (en) * 1994-09-14 1996-07-23 Merck & Co., Inc. Endothelin antagonists bearing 5-membered heterocyclic amides
US5559135A (en) * 1994-09-14 1996-09-24 Merck & Co., Inc. Endothelin antagonists bearing pyridyl amides
US6268369B1 (en) 1994-11-16 2001-07-31 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
SK60097A3 (en) 1994-11-16 1998-01-14 Synaptic Pharma Corp Dihydropyrimidines, pharmaceutical composition containing same and use thereof
CN1064965C (zh) * 1994-11-25 2001-04-25 弗·哈夫曼-拉罗切有限公司 新的磺酰胺类化合物及其作为药物的用途
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
US5837708A (en) * 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
WO1996016963A1 (de) * 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamide und deren verwendung als heilmittel
AU695255B2 (en) * 1994-12-20 1998-08-13 F. Hoffmann-La Roche Ag Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
TW313568B (ko) * 1994-12-20 1997-08-21 Hoffmann La Roche
PT801062E (pt) * 1994-12-28 2003-08-29 Kowa Co Derivados de pirimidina
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5780473A (en) * 1995-02-06 1998-07-14 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5573762A (en) 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
UA58494C2 (uk) 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) * 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
DE19527568A1 (de) 1995-07-28 1997-01-30 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
DE19528418A1 (de) * 1995-08-02 1997-02-06 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19530032A1 (de) * 1995-08-16 1997-02-20 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
JPH09124620A (ja) * 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
CZ260596A3 (en) * 1995-10-12 1997-12-17 Hoffmann La Roche Sulfonamide derivative, process of its preparation and pharmaceutical composition containing thereof
US6228861B1 (en) 1995-11-16 2001-05-08 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
RU2172735C2 (ru) * 1995-12-20 2001-08-27 Яманоути Фармасьютикал Ко., Лтд. Арилэтенсульфонамидные производные и фармацевтическая композиция
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
HUP0002351A3 (en) 1996-02-20 2001-10-29 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides, intermediates and process for preparing them
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5958905A (en) 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
US5804585A (en) 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
US6245773B1 (en) 1996-05-16 2001-06-12 Synaptic Pharmaceutical Corporation 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines
US6172066B1 (en) 1996-05-16 2001-01-09 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
CA2262676A1 (en) * 1996-08-09 1998-02-19 Merck & Co., Inc. Stereoselective deoxygenation reaction
US5985830A (en) * 1996-09-16 1999-11-16 Dalhousie University Use of IGF-I for the treatment of kidney disorders
US5883254A (en) * 1996-11-08 1999-03-16 Hoffmann-La Roche Inc. Process for making pyrimidine derivatives
DE19653024A1 (de) * 1996-12-19 1998-06-25 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
HRP980001A2 (en) * 1997-01-14 1998-10-31 Feng Xu Asymmetric conjugate addition reaction using a chiral additive
US5998625A (en) * 1997-01-14 1999-12-07 Merck & Co., Inc. Asymmetric conjugate addition reaction using a chiral additive
WO1998033781A1 (en) * 1997-01-30 1998-08-06 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
EE04156B1 (et) 1997-04-28 2003-10-15 Texas Biotechnology Corporation Sulfoonamiidid endoteliini vahendatud haiguste ravimiseks
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
US6022972A (en) 1997-08-08 2000-02-08 Merck & Co., Inc. Pyridine propanoic acid derivatives
US6410554B1 (en) 1998-03-23 2002-06-25 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6136971A (en) * 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
US6680323B2 (en) 1998-12-23 2004-01-20 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
US6274585B1 (en) 1998-12-23 2001-08-14 Synaptic Pharmaceutical Corporation Dihydropyrimidines and uses thereof
HUP0201320A2 (en) 1999-03-19 2002-08-28 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides and intermediates thereof
DE19916719A1 (de) * 1999-04-13 2000-10-19 Basf Ag Neue ECE-Inhibitoren, ihre Herstellung und Verwendung
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
HUP0204168A2 (hu) * 1999-12-22 2003-04-28 Actelion Pharmaceuticals Ltd. Butin-diol-származékok, ilyeneket tartalmazó gyógyszerkészítmény és előállítása
US6720322B2 (en) * 1999-12-22 2004-04-13 Actelion Pharamceuticals Ltd. Butyne diol derivatives
AU2464301A (en) 1999-12-31 2001-07-16 Encysive Pharmaceuticals Inc. Sulfonamides and derivatives thereof that modulate the activity of endothelin
KR100495550B1 (ko) * 2000-01-25 2005-06-16 에프. 호프만-라 로슈 아게 설폰아미드의 제조 방법
IL151017A0 (en) * 2000-02-11 2003-02-12 Juvantia Pharma Ltd Oy Compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor
US6521632B2 (en) 2000-02-11 2003-02-18 Oy Juvantia Pharma Ltd Method for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
US6670362B2 (en) 2000-09-20 2003-12-30 Pfizer Inc. Pyridazine endothelin antagonists
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
EP1345920B1 (en) 2000-12-18 2006-04-12 Actelion Pharmaceuticals Ltd. Novel sulfamides and their use as endothelin receptor antagonists
MXPA04000615A (es) * 2001-07-20 2004-04-20 Juvantia Pharma Ltd Oy Compuestos utiles para el tratamiento o la prevencion de enfermedades mediadas por alfa-2b-adrenoceptor.
FI116940B (fi) 2001-07-20 2006-04-13 Juvantia Pharma Ltd Oy Alfa-2B-adrenoseptorivälitteisen sairauden hoitoon tai ehkäisyyn käyttökelpoiset yhdisteet
FR2831446B1 (fr) * 2001-10-26 2004-03-05 Sanofi Synthelabo Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
GB0219660D0 (en) 2002-08-23 2002-10-02 Astrazeneca Ab Therapeutic use
US20040102361A1 (en) * 2002-11-27 2004-05-27 Frederic Bodin Pharmaceutical composition for the treatment of pulmonary arterial hypertension
ES2320649T3 (es) 2002-12-02 2009-05-27 Actelion Pharmaceuticals Ltd. Pirimidin-sulfamidas y su uso como antagonistas de receptores de endotelina.
US20050101608A1 (en) * 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
GB0327839D0 (en) 2003-12-01 2003-12-31 Novartis Ag Organic compounds
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
EP1729749A2 (en) 2004-03-17 2006-12-13 Novartis AG Use of renin inhibitors in therapy
EP1796653A2 (en) * 2004-07-26 2007-06-20 Actelion Pharmaceuticals Ltd. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
TW200628467A (en) 2004-11-11 2006-08-16 Actelion Pharmaceuticals Ltd Novel sulfamides
PL1883397T3 (pl) * 2005-05-17 2010-05-31 Actelion Pharmaceuticals Ltd Dyspergowalna tabletka bosertanu
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US20080233188A1 (en) 2005-09-12 2008-09-25 Actelion Pharmaceuticals Ltd. Stable Pharmaceutical Compositions Comprising a Pyrimidine - Sulfamide
ATE551059T1 (de) * 2005-10-26 2012-04-15 Asahi Kasei Pharma Corp Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
EP2351569B1 (en) 2005-10-26 2012-08-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
JP2009530284A (ja) * 2006-03-13 2009-08-27 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド 拡張期心不全を治療するための方法と組成物
MX2008011844A (es) * 2006-03-13 2008-10-02 Encysive Pharmaceuticals Inc Formulaciones de sitaxsentano de sodio.
RU2435585C2 (ru) * 2006-04-13 2011-12-10 Актелион Фармасьютиклз Лтд Антагонисты рецептора эндотелина, предназначенные для ранней стадии идиопатического фиброза легких
US20080026061A1 (en) * 2006-06-22 2008-01-31 Reichwein John F Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide
AU2007276433B2 (en) 2006-07-20 2011-06-16 Novartis Ag Amino-piperidine derivatives as CETP inhibitors
AR062501A1 (es) * 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
US8080549B2 (en) * 2007-01-12 2011-12-20 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
WO2008088727A2 (en) 2007-01-12 2008-07-24 Concert Pharmaceuticals, Inc. Endothelin receptor antagonists
US20080242687A1 (en) * 2007-04-02 2008-10-02 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
AU2008247169B2 (en) * 2007-05-08 2013-09-12 Generics [Uk] Limited Polymorphic forms of bosentan
EP2170841A1 (en) * 2007-06-29 2010-04-07 Merck Generics (UK) Limited Process for introduction of hydroxyethoxy side chain in bosentan
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
US20090069351A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched bosentan
EP2205591A1 (en) * 2007-10-11 2010-07-14 Actavis Group PTC EHF Novel polymorphs of bosentan
US8530488B2 (en) 2007-10-24 2013-09-10 Generics [Uk] Limited Crystalline forms of bosentan
WO2009059943A1 (en) 2007-11-05 2009-05-14 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
CA2707651A1 (en) 2007-12-03 2009-06-11 Novartis Ag 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis
ATE530531T1 (de) * 2007-12-18 2011-11-15 Dipharma Francis Srl Verfahren zur herstellung von bosentan
US8481730B2 (en) * 2008-01-01 2013-07-09 Cipla Limited Method of synthesis of Bosentan, its polymorphic forms and its salts
WO2009095933A2 (en) * 2008-01-10 2009-08-06 Msn Laboratories Limited Improved and novel process for the preparation of bosentan
US20110021547A1 (en) * 2008-01-24 2011-01-27 Actavis Group Ptc Ehf Substantially Pure and a Stable Crystalline Form of Bosentan
CA2712860C (en) 2008-02-08 2014-11-18 Abhay Gaitonde Process for preparing bosentan
CN101279948B (zh) * 2008-03-14 2010-08-11 苏州博鸿化工技术有限公司 4,6-二氯-5-(2-甲氧基苯氧基)-2,2'-二嘧啶的合成方法
WO2009141167A1 (en) * 2008-05-23 2009-11-26 Synthon B.V. Bosentan salts
JP2011523655A (ja) * 2008-06-03 2011-08-18 フレセニウス メディカル ケア ドイッチュランド ゲーエムベーハー ガンマセクレターゼモジュレータを含む医薬組成物
WO2010012637A1 (en) * 2008-08-01 2010-02-04 Inke, S.A. Process for the preparation of bosentan
WO2010015623A1 (en) * 2008-08-05 2010-02-11 Farmaprojects, S. A. Process for the preparation of endothelin receptor antagonists
WO2010032261A1 (en) * 2008-08-12 2010-03-25 Cadila Healthcare Limited Process for preparation of bosentan
CA2741928A1 (en) * 2008-11-03 2010-06-03 Generics [Uk] Limited Hplc method for the analysis of bosentan and related substances and use of these substances as reference standards and markers
IT1393136B1 (it) 2009-03-11 2012-04-11 Sifa Vitor S R L Procedimento per la preparazione del bosentan
US20100256371A1 (en) * 2009-04-02 2010-10-07 Glenmark Processes for the preparation of bosentan and its intermediates thereof
CA2758108A1 (en) 2009-04-13 2010-10-21 Sandoz Ag Process for preparation of endothelial receptor antagonist (bosentan)
BRPI1012852A2 (pt) 2009-05-15 2018-06-19 Novartis Ag derivados de benzoxazolona como inibidores da sintase de aldoesterona
SI2429995T1 (sl) 2009-05-15 2014-05-30 Novartis Ag Arilpiridini kot inhibitorji aldosteron sintaze
EP2435402B1 (en) 2009-05-28 2016-04-13 Novartis AG Substituted aminobutyric derivatives as neprilysin inhibitors
NZ596304A (en) 2009-05-28 2014-01-31 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
WO2011024056A2 (en) 2009-08-27 2011-03-03 Aurobindo Pharma Limited An improved process for the preparation of bosentan
EP2499131A2 (en) 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Crystalline forms of bosentan salts and processes for their preparation
EP2993169B1 (en) 2009-11-17 2017-12-20 Novartis AG Aryl-pyridine derivatives as aldosterone synthase inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
EP2509594A1 (en) 2009-12-09 2012-10-17 INSERM - Institut National de la Santé et de la Recherche Médicale Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis
EP2368884A1 (en) 2010-03-25 2011-09-28 Laboratorios Lesvi, S.L. Process for the preparation of bosentan
JP5850576B2 (ja) * 2010-07-06 2016-02-03 富士化学工業株式会社 ボセンタン固体分散体
WO2012020421A1 (en) 2010-08-11 2012-02-16 Megafine Pharma (P) Ltd. A novel process for preparation of bosentan
AU2011310754B2 (en) 2010-10-01 2016-12-15 Zach System S.P.A. Process for preparing Bosentan Monohydrate and its intermediates
WO2012056468A1 (en) 2010-10-13 2012-05-03 Matrix Laboratories Ltd A process for the preparation of bosentan
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
WO2012073135A1 (en) 2010-12-03 2012-06-07 Alembic Pharmaceuticals Limited An improved process for preparing bosentan
ES2386173B1 (es) * 2011-01-13 2013-06-25 Urquima, S.A. Proceso de preparación de un antagonista del receptor de la endotelina
WO2012139736A1 (en) 2011-04-11 2012-10-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Pharmaceutical composition comprising bosentan
JP6001650B2 (ja) * 2011-05-23 2016-10-05 昂科生物医学技術（蘇州）有限公司 Ｃｄｃ４２抑制剤およびその応用
WO2013098577A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of bosentan
US20130245259A1 (en) 2012-03-16 2013-09-19 Natco Pharma Limited Process for the preparation of bosentan monohydrate
ITMI20120701A1 (it) 2012-04-27 2013-10-28 Dipharma Francis Srl Procedimento per la purificazione di un composto benzensolfonammidico
EP2848245A4 (en) 2012-05-11 2016-01-27 Hanall Biopharma Co Ltd ORAL PREPARATION WITH CONTROLLED RELEASE OF BOSENTAN
JP2015521594A (ja) 2012-06-12 2015-07-30 カディラ ファーマシューティカルズ リミテッド ボセンタンの製造方法
WO2014033758A1 (en) 2012-08-31 2014-03-06 Rao Davuluri Ramamohan 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2(2-pyrimidinyl)-pyrimidine-4-yl)-benzen esulfonamide sodium
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
KR102004422B1 (ko) 2012-12-20 2019-07-26 제일약품주식회사 보센탄 일수화물의 제조방법, 이에 사용되는 신규 중간체 및 이의 제조방법
LT2956464T (lt) 2013-02-14 2018-07-10 Novartis Ag Pakeisti bisfenilbutanoinės fosfonrūgšties dariniai, kaip nep (neutralios endopeptidazės) inhibitoriai
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
MX2016001021A (es) 2013-07-25 2016-08-03 Novartis Ag Bioconjugados de polipeptidos de apelina sinteticos.
CN103554037B (zh) * 2013-11-08 2015-03-18 南京靖龙药物研发有限公司 一种波生坦代谢物羟基波生坦的制备方法
SG11201704758XA (en) 2015-01-23 2017-08-30 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
ES2584534B1 (es) 2015-03-27 2017-03-13 Retinset, S.L. Formulación tópica oftálmica de bosentan
WO2018185516A1 (en) 2017-04-05 2018-10-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
TWI833430B (zh) * 2021-11-08 2024-02-21 大陸商正大天晴藥業集團股份有限公司 氮雜聯苯類化合物及其應用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545944A1 (de) * 1964-06-19 1969-12-11 Hoffmann La Roche Verfahren zur Herstellung von neuen Sulfonamiden der Pyrimidinreihe
AU6623690A (en) * 1990-10-29 1992-05-26 Ibrahim Raouf Shimi Novel sulfamide derivatives, a method for obtaining them and their use as a drug

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100411358B1 (ko) * 1995-05-16 2004-07-05 다나베 세이야꾸 가부시키가이샤 술폰아미드유도체및그의제조방법

Also Published As

Publication number Publication date
JPH05222003A (ja) 1993-08-31
ES2152222T4 (es) 2011-10-28
CS180492A3 (en) 1992-12-16
JPH0730042B2 (ja) 1995-04-05
EE03028B1 (et) 1997-08-15
ZA924126B (en) 1993-02-24
CY2004005I2 (el) 2016-08-31
NO2002012I2 (no) 2005-09-26
IS3877A (is) 1992-12-14
HU9201930D0 (en) 1992-08-28
RO111268B (ro) 1996-08-30
IL102138A0 (en) 1993-01-14
EP0526708B1 (de) 2000-10-18
CA2071193C (en) 1998-08-25
NO303826B1 (no) 1998-09-07
SK279006B6 (sk) 1998-05-06
SG54209A1 (en) 1998-11-16
ATE197044T1 (de) 2000-11-15
TW222625B (ko) 1994-04-21
IE921920A1 (en) 1992-12-16
BR9202219A (pt) 1993-02-02
KR100235507B1 (ko) 1999-12-15
LU90976I2 (fr) 2002-12-16
NO922323L (no) 1992-12-14
NL300097I1 (nl) 2002-11-01
NO922323D0 (no) 1992-06-12
HUT63152A (en) 1993-07-28
DK0526708T3 (da) 2001-02-12
MX9202747A (es) 1994-05-31
CA2071193A1 (en) 1992-12-14
CY2306B1 (en) 2003-11-14
GR3035162T3 (en) 2001-04-30
EP0526708A1 (de) 1993-02-10
DZ1587A1 (fr) 2002-02-17
ES2152222T3 (es) 2001-02-01
FI112216B (fi) 2003-11-14
DE59209872D1 (de) 2000-11-23
IS2054B (is) 2005-10-14
FI922746A0 (fi) 1992-06-12
LU90975I2 (fr) 2002-12-16
BG60831B2 (bg) 1996-04-30
HU211683A9 (en) 1995-12-28
RU2086544C1 (ru) 1997-08-10
US5292740A (en) 1994-03-08
FI922746A (fi) 1992-12-14
HU221203B1 (en) 2002-08-28
IL102138A (en) 1996-09-12
PT526708E (pt) 2001-04-30
DE10299047I2 (de) 2009-11-05
CZ281434B6 (cs) 1996-09-11
AU653604B2 (en) 1994-10-06
CY2004005I1 (el) 2009-11-04
NZ243074A (en) 1994-11-25
AU1812192A (en) 1992-12-17
DE10299047I1 (de) 2003-03-27

Similar Documents

Publication Publication Date Title
KR930000489A (ko) 설폰아미드
JP2004517925A5 (ko)
KR950005825A (ko) 4-아미노피리미딘 유도체
NO164294C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive alken-, alkyn-, eller cykloalkylenderivater.
KR960014102A (ko) 인돌로일구아니딘 유도체
DE3587568D1 (de) Diazepine enthaltende pharmazeutische Zusammensetzungen mit Plättchen aktivierender Faktor (PAF)-antagonistischer Wirkung.
GB1464907A (en) 5-6-substituted benzimidazole-2-carbamate derivatives having anthelmintic act'ity
SE7606913L (sv) Orgnisk forening
IT1226727B (it) Farmaci precursori della dopamina.
KR920021508A (ko) 치환된 디아미노프탈이미드 및 동족체
DK468288D0 (da) Antivirale forbindelser
KR850002970A (ko) 시클로헥세놀 유도체의 제조방법
KR920002579A (ko) 종양치료 조성물 및 치료방법
SV1998000119A (es) Formulacion medicamentosa con liberacion controlada de sustancia activa. ref. lea 32671-sv
FI922044A0 (fi) Ny polypeptid och daerav framstaelld hiv-medicin.
ATE30019T1 (de) Bicyclooxyarylthioharnstoffe und herstellungsverfahren.
FI913034A0 (fi) Foerening med magsyrainhiberande effekt och foerfarande foer dess framstaellning.
KR920012049A (ko) 불소 화합물
KR950032147A (ko) 아실화된 아미노알칸이미다졸 및 -트리아졸
KR930021616A (ko) (1h-인돌-1-일)-2-(아미노)아세트아미드 및 관련 (1h-인돌-1-일)-(아미노알킬)아미드, 이를 제조하기 위한 중간체 및 제조방법, 및 약제로서의 이의 용도
ATE285771T1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
ES8505199A1 (es) Un procedimiento para la preparacion de derivados de difenilalquilenicos.
AR032891A1 (es) Compuesto derivado de hidroxiimino-fluoreno y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de proteinquinasa
CA2140781A1 (en) Pharmocologically active .alpha.-¬tertiary-aminomethyl|- benzenemethanol derivatives
ES2181132T3 (es) Derivados de benzo(b)tiofeno para disminuir el contenido de plaquetas.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20110830

Year of fee payment: 13

EXPY Expiration of term